Loading patent…
AssigneeAntibody and Receptor Therapeutics Co., Ltd.
InventorsDong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
Estimating the term…
The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
A method for treating a myostatin-related disease, comprising administering an extracellular water-soluble domain of a delta-like 1 homolog (DLK1), a fragment of the extracellular water-soluble domain of DLK1, a mutant of the extracellular water-soluble domain of DLK1, or a fragment of the mutant as an active ingredient.
A kit for diagnosing a myostatin-related disease, comprising an antibody or an aptamer specifically binding to DLK1-myostatin, DLK1-ACVR2B or a soluble fragment thereof.
14-20. (canceled)
Dependencies are inferred from the claim text.